SCHEMBL5756977

SCHEMBL5756977

Cc1ccc(CCNC(=O)c2ccc(C)n(-c3cccc(C#N)c3)c2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.47
ELANE P08246 1/20 0.47
CNR2 P34972 2/20 0.46
CNR1 P21554 1/20 0.46
NOTUM Q6P988 1/20 0.45
GAA P10253 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.41
KLKB1 P03952 1/20 0.41
KLK1 P06870 1/20 0.41
MYC P01106 1/20 0.41
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27643772 0.93 KLKB1 (0.48) TP53ELANECNR2CNR1NOTUM
SCHEMBL5757117 0.92 ELANE (0.47) TP53ELANECNR2CNR1NOTUM
SCHEMBL5756759 0.92 CNR1 (0.47) TP53ELANECNR2CNR1NOTUM
SCHEMBL5757207 0.92 ELANE (0.45) TP53ELANECNR2CNR1NOTUM
SCHEMBL5756911 0.90 ELANE (0.57) TP53ELANENOTUMGAARXFP1
SCHEMBL5758805 0.89 ELANE (0.51) ELANERXFP1LMNAMAPTALDH1A1
SCHEMBL5756339 0.88 LMNA (0.50) TP53GAARXFP1LMNAMAPT
SCHEMBL5757706 0.88 ELANE (0.45) TP53ELANECNR2CNR1NOTUM
SCHEMBL5757736 0.88 NOTUM (0.43) TP53ELANECNR2CNR1NOTUM
SCHEMBL5755743 0.88 RAB9A (0.49) ELANECNR2CNR1NOTUMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 TP53 3353/4885ELANE 2/4885CNR2 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.